In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54% over the past four weeks, there is light at the end of the tunnel as it is now in ...

During this time the fighting went on, and the Australian cooperation with ARVN grew. Viet Cong strength was growing, and the heavily armed NVA was slowly pushing downwards towards Saigon ...

Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports.

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.